Dissertations / Theses on the topic 'Hepatocellular cancer, p21, p53'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 23 dissertations / theses for your research on the topic 'Hepatocellular cancer, p21, p53.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
BENNETT, RICHARD A. "The p53-p21-Cyclin E Pathway in Centrosome Amplification and Chromosome Instability." University of Cincinnati / OhioLINK, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1189188730.
Full textLu, Wenjing, and 鲁文静. "The interaction of mortalin and p53 in human hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46330069.
Full textLehmkuhl-Dakhwe, K. Virginia. "Regulation of p53, p21, ARF, BIM, and BAX by the Transcription Factor Trip-Br1." Ohio University / OhioLINK, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1194549826.
Full textEnane, Francis Obunyakha. "HEPATOCYTE DIFFERENTIATION AND HEPATOCELLULAR CARCINOMA: RATIONALE FOR P53 INDEPENDENT THERAPY." Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1491570319727552.
Full textCampbell, Kevin. "The use of Sphingomyelin to protect against UV induced DNA damage in Human Keratinocytes." DigitalCommons@CalPoly, 2015. https://digitalcommons.calpoly.edu/theses/1413.
Full textSheel, Ankur. "Identification of Essential Genes in Hepatocellular Carcinomas using CRISPR Screening." eScholarship@UMMS, 2019. https://escholarship.umassmed.edu/gsbs_diss/1039.
Full textWilce, Alice J. "Understanding the function and mechanisms of intestinal cell kinase in the growth and survival of prostate cancer cells." Thesis, Queensland University of Technology, 2015. https://eprints.qut.edu.au/85439/1/Alice_Wilce_Thesis.pdf.
Full textMorrison, Chevaun Danielle. "DYNAMIC INTERACTIONS OF P53 AND C-ABL IN REGULATING BREASTCANCER PROGRESSION AND METASTASIS." Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1481208229508494.
Full textRoger, Lauréline. "Etude des mécanismes de la régulation de l'EMT par le suppresseur de tumeur p53 dans un modèle de cellules de carcinome du colon." Montpellier 2, 2007. http://www.theses.fr/2007MON20182.
Full textThe p53 tumour suppressor gene encodes a transcriptional regulator that monitor proliferation signals to prevent cells from uncontrolled growth. However, p53 has also alternative functions. Notably, loss of p53 favours cell migration and invasion, processes involved in tumour metastasis. Given that epithelial to mesenchymal transition (EMT) also increases cell migration by altering the cell phenotype and morphology, we hypothesized that p53 controls molecular alterations that mediate EMT during cancer progression. Analysis of E-cadherin promoter activity and chromatin immunoprecipitation identified p53 as a direct transcriptional repressor of E-cadherin in human colon carcinoma cells, HCT116. Aberrant levels of p53 disrupted E-Cadherin-based cell-cell contacts and induced a more mesenchymal phenotype with downregulation of E-Cadherin and induction of the mesenchymal gene, vimentin. In addition, p21Waf-1 impeded p53 transcriptional repression and restored in part cell to cell adhesion. Furthermore, HCT116p53-/- cells overexpressing dominant-negative form of p53 also displayed the EMT-like phenotype. Neither p53 nor mutant p53–mediated shift toward mesenchymal morphology led to an increase of cell invasiveness. This work and our previous finding of mutant p53-mediated cell invasion identify p53 as a novel regulator of EMT and offer new perspectives in the comprehension of metastasis
Harr, Michael. "The Interactive Transcript Abundance Index [c-myc*p73á]/[p21*Bcl-2] Correlates With Spontaneous Apoptosis and Response to CPT-11: Implications for Predicting Chemoresistance and Cytotoxicity to DNA Damaging Agents." University of Toledo Health Science Campus / OhioLINK, 2006. http://rave.ohiolink.edu/etdc/view?acc_num=mco1176730845.
Full textPfister, Christian. "Analyse de marqueurs moléculaires dans la cancérogénèse vesicale." Rouen, 1999. http://www.theses.fr/1999ROUE05NR.
Full textAhronian, Leanne G. "Identification and Characteristics of Factors Regulating Hepatocellular Carcinoma Progression and Metastasis: A Dissertation." eScholarship@UMMS, 2014. https://escholarship.umassmed.edu/gsbs_diss/705.
Full textAhronian, Leanne G. "Identification and Characteristics of Factors Regulating Hepatocellular Carcinoma Progression and Metastasis: A Dissertation." eScholarship@UMMS, 2003. http://escholarship.umassmed.edu/gsbs_diss/705.
Full textJacquot, Catherine. "Recherche d'une activite anti-oncogenique (genes cles p53/p21 et nouveaux genes) dans un modele cellulaire de cancer bronchopulmonaire non a petites cellules (nsclc-n6) prealablement induit en differenciation terminale atypique." Nantes, 2001. http://www.theses.fr/2001NANT05VS.
Full textDoumont, Gilles. "Identification et caractérisation de nouveaux médiateurs de l'activité biologique de la protéine suppresseur de tumeur p53." Doctoral thesis, Universite Libre de Bruxelles, 2005. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/211022.
Full textp53 constitue un facteur de transcription qui se lie à des séquences particulières de l'ADN et active l'expression des gènes adjacents. L'expression orchestrée de ces gènes conduit, directement ou indirectement et suivant le contexte cellulaire, soit à la mort de la cellule soit à l'inhibition de la division cellulaire.
Les mécanismes moléculaires médiant ces deux activités biologiques essentielles de p53, de même que les mécanismes influençant le choix de la réponse cellulaire, sont encore mal compris. L'importance de p53 dans ce choix reste également à démontrer.
Afin de contribuer à la compréhension de ces mécanismes, le modèle murin déficient pour Mdm4, un régulateur négatif de l'activité de p53, a été choisi. L'inactivation de Mdm4 chez la souris conduit en effet à l'activation ectopique de p53 in vivo et l'induction de deux types de réponse: apoptose dans le neuroépithélium et arrêt de la prolifération cellulaire dans les tissus non neuronaux. Le profil d'expression des gènes dans les tissus neuronaux et non neuronaux a donc été comparé entre embryons de souris sauvage et mdm4-/- par la technique d'hybridation de biopuces à ADN. Les résultats obtenus suggèrent que le type de réponse dépend du type cellulaire et non de p53 lui-même. En effet les profils d'expression des gènes dans les tissus neuronaux (conditions d'apoptose) et non neuronaux (conditions d'arrêt de la prolifération cellulaire) chez l'embryon de souris mdm4-/- sont comparables.
Nous nous sommes ensuite particulièrement intéressés à deux nouveaux gènes dont l'expression est augmentée dans les embryons mdm4-/-. Dans un premier temps, leur induction transcriptionnelle chez l'embryon de souris mdm4-/- a été confirmée par différentes techniques et il a été vérifié qu'ils constituaient tous deux des cibles directes de p53 induites suite à un stress génotoxique.
Le premier gène code Dapk1, une protéine suppresseur de tumeur pro-apoptotique présentant une activité de type sérine/thréonine kinase. Ce travail a permis d'établir que Dapk1 participait à une boucle de rétroaction du contrôle de l'activité de p53.
Le deuxième gène identifié code la protéine Ptprv, un récepteur transmembranaire présentant une activité de type tyrosine phosphatase. En vue d'étudier la signification physiologique de l'induction transcriptionnelle de ptprv suite à l'activation de p53, des expériences effectuées à partir de matériel biologique issu de souris déficientes pour Ptprv ont été réalisées. Ces expériences confirment le rôle essentiel de Ptprv comme médiateur de l'arrêt du cycle cellulaire en phase G1 induit par p53 suite à un stress génotoxique, à la fois in vitro et in vivo. Par contre, Ptprv ne semble pas influencer l'apoptose induite suite à l'activation de p53. Ce travail a également permis d'établir le rôle essentiel de Ptprv dans la suppression de tumeurs induites chez la souris par activation constitutive de l'oncogène Ras.
Doctorat en sciences, Spécialisation biologie moléculaire
info:eu-repo/semantics/nonPublished
TAROCCHI, MIRKO. "Role of Kruppler-like factor 6 in the hepatocellular carcinoma development." Doctoral thesis, 2011. http://hdl.handle.net/2158/591962.
Full textPok, Sharon. "Role of cyclin E in the pathogenesis of hepatocellular carcinoma." Phd thesis, 2013. http://hdl.handle.net/1885/9932.
Full textFU, CHIEN-LANG, and 傅建郎. "Tumor suppressor gene p53/p21 in colorectal cancer cell distribution of nucleus and cytoplasmic with colorectal cancer." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/rws295.
Full text元培醫事科技大學
醫學檢驗生物技術系碩士班
105
In order to prevent cell transformation, when the tumor suppressor gene p53 mutates, it will cause cell proliferation and lead to tumor. P21 is a downstream regulator of p53, which is associated with colorectal cancer differentiation, depth of invasion, proliferation and metastasis. In recent years, various studies have pointed out that in the context of p53 mutation, p21 expression increased, but may cause tumor proliferation and metastasis. Litchi kernel extract is rich in polyphenols and is resistant to colon or rectal cancer. In this experiment, nude mice bearing the p53 mutant HT-29 cells transplanted with the litchi kernel extract showed a dose-dependent decrease in the expression of p53 and p21. However, in nude mice bearing tumors of SW480 cells, a dose-dependent decrease in p53 was seen. However, the performance of p21 was not significantly reduced compared to the results of HT-29. The results show that the litchi kernel extracts of HT-29 mutant p53 and p21 performance will have an inhibitory effect, and in cell experiments, the p53 mutant cell line HT-29 found p53 and p21 performance with the lychee kernel extract dose increases with a downward trend. On the p53-null mutant SW480, p53 was seen to decrease with increasing doses, but there was no significant reduction in the portion of p21. Based on all the above results of this experiment, we can confirm that the application of litchi nuclear extract in p53 mutant colorectal cancer has its influence, and can affect the expression of its downstream p21, we can expect by inhibiting the mutation in p53 and in Its absence of p21 environment, in order to achieve the effect of inhibiting colorectal cancer.
"ZBP-89 expression in hepatocellular carcinoma and its interaction with mutant p53." Thesis, 2011. http://library.cuhk.edu.hk/record=b6075357.
Full textThesis (Ph.D.)--Chinese University of Hong Kong, 2011.
Includes bibliographical references (leaves ).
Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Abstract also in Chinese.
"ZBP-89 regulates Bak expression via epigenetic mechanism." 2013. http://library.cuhk.edu.hk/record=b5549831.
Full text肝癌是非常高死亡率的恶性肿瘤之一。由于传统化疗方式的局限性,表观遗传治疗方法可能成为肝癌治疗的替代方法。研究报道ZBP-89诱导肝癌细胞Bak的表达,表观调控是否参与该诱导作用,目前仍然不清楚。
HDAC3被认为是化疗靶点和肝癌复发的肿瘤标记物。它常常在肝癌组织中高表达,对HDAC3的抑制作用可以增加肝癌的化疗效果。我们的研究表明ZBP-89可以降低肝癌细胞HDAC3的表达,但机制未明。蛋白的翻译后调控是细胞生化过程的重要调节因素。所以,研究调节HDAC3的降低途径对肝癌的发生和复发具有非常重要的研究意义。
本研究旨在研究ZBP-89调控Bak表达的表观遗传机制。同时,弄清楚DNA甲基化转移酶和组蛋白去乙酰化酶是否参与ZBP-89对Bak的调控作用,进一步阐明ZBP-89对HDAC3降低通路的机制。
方法和结果
肝癌病人组织蛋白分析表明,相对于癌旁组织,肝癌组织Bak和ZBP-89蛋白表达降低,而DNMT1和HDAC3表达升高。免疫共沉淀技术显示ZBP-89与HDAC3、 DNMT1结合,但不与HDAC4, DNMT3a和DNMT3b结合。相应地,HDAC3和 DNMT1免疫沉淀分析也显示三者形成免疫复合物。我们在肝癌细胞中过表达ZBP-89,验证它会不会影响HDACs和DNMTs的活性。实验结果表明过表达的ZBP-89抑制HDACs和DNMTs的活性。进一步发现ZBP-89调节的Bak表达可能是通过抑制HDACs活性和维持组蛋白H3和H4乙酰化水平实现的。另一方面,我们同样证明HDAC的抑制剂(HDACi)VPA和TSA可以诱导肝癌细胞Bak表达,此外,siRNA干扰HDAC3的表达同样可以诱导Bak表达。
对DNMT1表达的抑制和使用DNMT抑制剂(DNMTi)Zebularine也可以诱导Bak的表达。染色质免疫沉淀结果显示ZBP-89结合于Bak的启动子区域,从-3188bp到-3183bp,从-275到-49。 ZBP-89可以抑制DNMT的活性,那么ZBP-89是否会影响DNA中CpG岛甲基化状态和甲基化结合蛋白(MeCP2)的结合能力,这一点仍需要进一步证实。结果表明ZBP-89可以抑制MeCP2结合基因组DNA。为进一步揭示MeCP2是否由于启动子区域CpG岛去甲基化影响其结合能力,我们采用亚硫酸盐测序方法。测序结果显示ZBP-89过表达可以影响Bak启动子CpG岛的甲基化状态,并促进其去甲基化。
腺病毒介导的ZBP-89过表达降低HDAC3表达呈现剂量依赖性,然而HDAC3 的mRNA水平并没有受到ZBP-89的表达。免疫共沉淀方法和蛋白免疫印迹实验用于分析Pin1和HDAC3复合物,磷酸化IκB和HDAC3复合物的结合情况。结果表明Pin1结合HDAC3并促进HDAC3的减少。同时,HDAC3与磷酸的IκB结合并进入蛋白减少途径。
构建的mU6-siPin1表达质粒用于敲除肝癌细胞Pin1的表达,方法检测基因表达水平。Pin1的缺失表达阻碍ZBP-89介导的HDAC3降低。在Pin1 敲除细胞系 JB6 C141 Pin1⁻/⁻ 和Pin1过表达细胞系的研究,ZBP-89更加能促进Pin1⁺/⁺细胞中HDAC3减少,而对Pin1⁺/⁺的细胞则没那么明显。由此肯定了Pin1在ZBP-89介导的HDAC3降低中的重要作用。进一步研究发现, IκB激酶 (IKK)抑制剂,CAY10576,能抑制 ZBP-89介导的HDAC3的降低;而SN50, p65/p50人核抑制多肽,则不影响HDAC3的降低。研究结果证明HDAC3的降低依赖IκB通路,而不是NF- κB活性。
我们用人肝癌细胞的裸鼠移植瘤模型研究ZBP-89调控Bak表达的表观遗传机制,及其对肝癌的治疗效果。研究结果表明ZBP-89蛋白和组蛋白抑制剂VPA和DNA甲基化抑制zebularine都能抑制肿瘤的生长,并诱导肿瘤组织Bak表达及细胞凋亡。VPA和zebularine联合治疗的效果更好。研究也表明ZBP-89可以在体内降低HDAC3蛋白水平。
结论
本研究揭示了ZBP-89调节Bak蛋白表达和肝癌细胞凋亡的表观遗传机制。同时,进一步揭示ZBP-89联合Pin1经由IκB通路调节HDAC3降低的机制. 本研究为肝癌表观遗传学的治疗提供研究基础和科学依据。
Background
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide with a very high mortality. Because the success of the conventional therapies is limited, epigenetic therapy may represent an alternative for HCC management. ZBP-89 is known to induce Bak in HCC. However, it is unclear whether epigenetic mechanisms contribute to ZBP-89-mediated Bak.
Histone acetylase 3 (HDAC3) is realized as a chemotherapy target and a biomarker of recurrence in HCC. HDAC3 is frequently overexpressed in HCC and its inhibition enhances the efficacy of anti-HCC chemotherapy. The pilot data have indicated that ZBP-89 reduced HDAC3 in HCC but the mechanism responsible was unknown. The post-translational modification of proteins functions as a key regulatory factor in cellular physiological procedures, such as ubiquitinoylation degradation. As a biomarker of HCC development and recurrence, it is important to understand how ZBP-89 mediates the reduction of HDAC3.
This study focuses on if ZBP-89 regulates Bak expression through epigenetic mechanisms. It is designed to investigate whether DNA methyltransferases (DNMTs), histone acetylases (HDACs) are involved in regulation of ZBP-89-induced Bak expression. The study also elucidates the mechanism how ZBP-89 reduces the level of HDAC3 protein.
Methods and Results
The levels of Bak and ZBP-89 as shown on western blots were reduced but DNMT1 and HDAC3 were increased in HCC cancer tissues compared to the corresponding non-cancer tissues. Co-immunoprecipitation experiments showed that ZBP-89 bound to HDAC3 and DNMT1 but not other epigenetic enzymes, such as HDAC4, DNMT3a and DNMT3b. To clarify if ZBP-89 affects the activities of HDACs and DNMTs, ZBP-89 was overexpressed in HCC cells. Enzyme activities of HDACs and DNMTs were determined using relevant assay kits. Results showed that overexpressed ZBP-89 inhibited the activities of HDACs and DNMTs. Further experiments indicated that ZBP-89-mediated Bak up-regulation might contribute to maintenance of histone H3 and H4 acetylation through inhibition of HDACs activity. In another set of experiments, we also found an increased Bak expression in HCC cells when the cells were treated with HDAC inhibitors (HDACi) VPA and TSA. HDAC3 siRNA also increased Bak expression.
Both knockdown of DNMT1 expression and administration of DNMTs inhibitors (zebularine) induced Bak expression. Chromatin immunoprecipitation (ChIP) showed that ZBP-89 bound to Bak promoter at the region from -3188bp to -3183bp and from -275 to -49. As ZBP-89 inhibits DNMT activity, it is essential to know whether its inhibition affectes DNA CpG methylation status and methyl-CpG binding protein (MeCP) binding. The results showed that ZBP-89 overexpression inhibited MeCP2 binding to genomic DNA. The finding indicated that decreased MeCP2 binding to DNA might be due to decreased methyl-CpG number in Bak promoter, suggesting that ZBP-89 might affect CpG island methylation status. Therefore, the bisulfite modified DNA sequencing method was used to clarify if Bak promoter CpG island methylation status was altered after ZBP-89 overexpression. Results revealed that ZBP-89 overexpression could demethylate the CpG islands in Bak promoter.
ZBP-89 overexpression dose-dependently reduced the expression of HDAC3 at protein level but not at mRNA level. Co-immunoprecipitation and western blot methods were used to analyze Peptidyl-prolyl cis/trans isomerase 1 (Pin1) and HDAC3, phospho-I kappa B (pIκB), and the result revealed that HDAC3 could bound with either Pin1 or pIκB to promote the reduced expression of HDAC3.
Constructed mU6-siPin1 vector was used to knockdown Pin1 expression in HCC cells. We found that knockdown of Pin1 expression blocked ZBP-89-mediated HDAC3 reduction. Experiments performed in Pin1 allele-knockdown JB6 C141 Pin1⁻/⁻ and Pin1⁺/⁺ cells showed that the reduction of HDAC3 by ZBP-89 was greater in Pin1⁺/⁺ cells than in Pin1⁻/⁻ cells, confirming the role of Pin1 in ZBP-89-mediated HDAC3 reduction. Furthermore, the ZBP-89-mediated HDAC3 reduction was suppressed by CAY10576, an IκB kinase (IKK) activation inhibitor but not by SN50, a p65/p50 translocation inhibitor, suggesting that HDAC reduction may depend on IκB kinase rather than NF-κB activity.
HCC xenograft mouse model was used to support the involvement of epigenetic mechanism in ZBP-89-induced Bak expression and its therapeutic effects against HCC. Results showed that ZBP-89 as well as HDAC inhibitor valproic acid (VPA) or/and DNMT inhibitor zebularine stimulated Bak expression and induced apoptosis of tumor cells in an HCC xenograft mouse model, arresting tumor growth. In HCC xenografe model, treatment by injection of Ad-ZBP-89 viral expression vector mediated ZBP-89 expression decreased HDAC3 expression, but not HDAC4.
Conclusions
In conclusion, the study demonstrates a novel mechanism through which ZBP-89 mediates an epigenetic pathway to promote Bak expression, and induce apoptosis in HCC cells. It also reveals the mechanism of HDAC3 reduction by ZBP-89 is dependent on IκB, which requires the presence of Pin1. This pathway may help develop future epigenetic therapy against HCC.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Ye, Caiguo.
Thesis (Ph.D.)--Chinese University of Hong Kong, 2013.
Includes bibliographical references (leaves 123-140).
Abstracts also in Chinese.
Abstract --- p.i
摘要 --- p.v
Publications --- p.viii
Acknowledgements --- p.ix
Abbreviations --- p.xi
List of Tables --- p.xiii
List of figures --- p.xiv
Chapter Chapter One: --- General Introduction --- p.1
Chapter 1.1 --- Background --- p.2
Chapter 1.2 --- The complexity of HDAC family and functions --- p.3
Chapter 1.2.1 --- HDAC family --- p.4
Chapter 1.2.2 --- Multifunction of HDACs --- p.6
Chapter 1.3 --- HDACs and apoptosis --- p.6
Chapter 1.3.1 --- HDAC regulates apoptotic-related gene expression --- p.9
Chapter 1.3.2 --- HDACs regulate apoptosis through protein complexes --- p.18
Chapter 1.3.3 --- HDACs mediates non-histone deacetylation and apoptosis --- p.21
Chapter 1.3.4 --- HDACs degradation deficiency and apoptosis --- p.24
Chapter 1.4 --- DNMTs and epigenetic modification --- p.25
Chapter 1.4.1 --- DNMT family --- p.25
Chapter 1.4.2 --- CpG islands methylation and HCC --- p.26
Chapter 1.5 --- Perspectives --- p.28
Chapter Chapter Two: --- ZBP-89 up-regulates Bak expression through inhibition the activity of HDACs and DNMTs --- p.30
Chapter 2.1 --- Introduction --- p.31
Chapter 2.2 --- Materials and Methods --- p.33
Chapter 2.2.1 --- Hepatocellular carcinoma patient samples and cell lines --- p.33
Chapter 2.2.2 --- Chemicals and reagents --- p.34
Chapter 2.2.3 --- Cell proliferation --- p.34
Chapter 2.2.4 --- Adenovirus infection of cells --- p.35
Chapter 2.2.5 --- Apoptosis detection --- p.36
Chapter 2.2.6 --- Transfection of siRNA and plasmid --- p.36
Chapter 2.2.7 --- Co-immunoprecipitation (co-IP) --- p.37
Chapter 2.2.8 --- Western blotting --- p.37
Chapter 2.2.9 --- Immunohistochemistry and Immunofluorescence --- p.38
Chapter 2.2.10 --- Chromatin immunoprecipitation --- p.38
Chapter 2.2.11 --- Sodium bisulfite modified sequencing of Bak promoter --- p.40
Chapter 2.2.12 --- Histone deacetylase activity assay --- p.41
Chapter 2.2.13 --- DNA methyltransferases enzyme activity --- p.42
Chapter 2.2.14 --- Xenograft animal model --- p.43
Chapter 2.2.15 --- Statistical analysis --- p.43
Chapter 2.3 --- Results --- p.45
Chapter 2.3.1 --- ZBP-89 interacts with DNMT1 and HDAC3 --- p.45
Chapter 2.3.2 --- DNA methyltransferase-1 and histone deacetylase 3 are overexpressed in cancer tissues --- p.48
Chapter 2.3.3 --- Inhibition of HDACs and DNMTs induces Bak expression and apoptosis --- p.58
Chapter 2.3.4 --- Adenovirus mediated ZBP-89 expression inhibits HDACs activity --- p.65
Chapter 2.3.5 --- ZBP-89 suppresses DNMTs activity --- p.67
Chapter 2.3.6 --- Overexpressed ZBP-89 demethylates methyl-CpG islands --- p.69
Chapter 2.3.7 --- Downregulation of HDAC3 and DNMT1 enhances Bak expression --- p.74
Chapter 2.3.8 --- Xenograft nude mouse model reveals that Ad-ZBP-89 adenovirus diminishes tumor volume and induces Bak expression and apoptosis --- p.75
Chapter 2.4 --- Discussion --- p.81
Chapter Chapter Three: --- ZBP-89 targets IkappaB to reduce HDAC3 via a Pin1-dependent pathway --- p.86
Chapter 3.1 --- Introduction --- p.87
Chapter 3.2 --- Materials and Methods --- p.89
Chapter 3.2.1 --- Cell lines, chemicals and reagents --- p.89
Chapter 3.2.2 --- Transfection of siRNA plasmid --- p.89
Chapter 3.2.3 --- Plasmid extraction by mini-prep --- p.90
Chapter 3.2.4 --- Co-immunoprecipitation (co-IP) and Western blotting --- p.91
Chapter 3.2.5 --- Total RNA extraction --- p.92
Chapter 3.2.6 --- Reverse transcription and real-time PCR --- p.93
Chapter 3.2.7 --- Immunohistochemistry and Immunofluorescence --- p.94
Chapter 3.2.8 --- Xenograft animal model --- p.95
Chapter 3.2.9 --- Statistical analysis --- p.95
Chapter 3.3 --- Results --- p.97
Chapter 3.3.1 --- ZBP-89 overexpression diminishes HDAC3 expression but not HDAC4 --- p.97
Chapter 3.3.2 --- Knockdown of Pin1 blocks ZBP-89-mediated HDAC3 reduction --- p.99
Chapter 3.3.3 --- ZBP-89 reduces the level of IκB --- p.103
Chapter 3.3.4 --- IκB degradation inhibitors suppresses ZBP-89-meditaed HDAC3 reduction --- p.105
Chapter 3.3.5 --- ZBP-89 decreases HDAC3 but increases Bak in xenograft tumor tissues --- p.111
Chapter 3.4 --- Discussion --- p.115
Chapter Chapter Four: --- Conclusions and Future Perspectives --- p.119
Chapter 4.1 --- Summary of results --- p.120
Chapter 4.2 --- Conclusions --- p.121
Chapter 4.3 --- Future Perspectives --- p.121
References --- p.123
Hadnagy, Annamaria. "Histone H2A exogène induit à différenciation et la sénescence des cellules cancéreuses." Thèse, 2008. http://hdl.handle.net/1866/8211.
Full textLiu, Chun-Yen, and 劉俊彥. "Study of a novel indolylquinoline compound that induces apoptosis in human non-small cell lung cancer and hepatocellular carcinoma cells through p53 activation." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/26208319107833898957.
Full text國立臺灣師範大學
生命科學系
104
Lung cancer is the leading cause of cancer mortality worldwide. NSCLC accounts for about 75% to 80% of lung cancer cases. Chemotherapy adverse side effects and resistance to current anticancer agents have been the pressing problems in the success of lung cancer therapy. Anticancer drugs are in urgent need especially for lung cancer. A program to develop a new anti-lung cancer agent by screening novel synthetic compounds was initiated. EMMQ was selected by MTT cell viability assay. The cell growth rate of A549 and H460 NSCLC cells was reduced by a low concentration of EMMQ treatment. Our study revealed that EMMQ induced apoptosis in NSCLC cells with wild-type p53, while the drug is less potent to against p53-null cells. The study elucidated that EMMQ-induced apoptosis is was mediated through the intrinsic pathway involving DNA damage, activation of p53, interference of mitochondrial ΔΨm that led to release of cytochrome c and down regulation Bcl-2, activation of caspase family proteins, and finally cleavage of PARP polymerase cleavage. In vivo study showed that EMMQ reduced tumorigenesis and significantly suppressed growth rate of xenograft tumors in nude mice. In addition, metastasis studies demonstrated that EMMQ may inhibit wild-type p53 cells migration at low concentration. In conclusion, EMMQ was demonstrated as an effective p53 regulator in NSCLC cells. Our findings indicate that EMMQ may serve as a promising new and potential therapeutic agent for human lung cancer. Human liver cancer is the fifth most frequently diagnosed cancer worldwide. The important limitation in the clinical battle against this tumor is its marked intrinsic and acquired refractivity to the available chemotherapies. Anticancer agents effective against chemo-resistant cells are greatly needed for liver cancer treatment. Previously, our study have identified EMMQ as an effective drug in the treatment of lung cancer cells in vitro and in animal models. In this work, results show EMMQ treatment may inhibit cell growth and induce apoptosis in HCC. EMMQ induced apoptosis in HCC cells with wild-typed p53, and is less potent in cells with mutant p53 and in p53-null. The study also demonstrated that EMMQ induces apoptosis through two major pathways. First, the compound induced cell death through the intrinsic pathway by first damaging DNA increasing expression of p53 and γ-H2AX and decreasing cyclin D1 and CDK 2, finally leading to G1 arrest in HepG2 cells as studied cell cycle. Second, the tumor suppressor gene p53 was activated following a reduction of ΔΨm, ROS generation and down-regulating Akt, Bcl-2, Bax, cytochrome c, caspase-3 and cleavage of PARP, the critical events leading to cell death in HepG2 cells treated with EMMQ. The in vitro findings indicate that EMMQ is a promising candidate for the treatment of liver cancer.
Tsou, Yu-Ching, and 鄒毓晴. "Study on the doxorubicin-elicited p38 MAPK pro-survival signaling in the control of p53/p21/Bcl-2/Bax/caspase-3 system in A549 lung cancer cells." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/73197074369923011747.
Full text